

Ambee Pharmaceuticals PLC
2nd Quarter Accounts(Un-Audited)
October to December-2024

Ambee Pharmaceuticals PLC
Statement of Financial Position (Un-audited)
As at 31st December 2024

Taka '000

Particulars	Notes	31st Dec. 2024	30 June.2024
ASSETS			
Non-Current Assets:		90,859	85,102
Property, Plant & Equipment -Carrying Value	3	90,133	83,834
Right-of-Use Asset		726	1,268
Current Assets:		647,753	504,843
Inventories	4	249,938	221,914
FDR Investment		50,000	-
Trade Receivable		204,522	180,645
Advance Income Tax	5	23,915	21,297
Advances, Deposits and Pre-payments	6	43,224	48,245
Cash and Cash Equivalents	7	76,154	32,742
Total Assets		738,612	589,945
EQUITY AND LIABILITIES			
Capital and Reserves:		30,191	29,425
Share Capital		24,000	24,000
Tax-Holiday Reserve		5,134	5,134
Retained Earnings- As per statement of changes in equity		1,057	291
Non-Current Liabilities:		4,787	4,758
Deferred Tax Liabilities	Annexure-A	4,579	4,513
Lease Finance (Non-Current Portion)	8 (A)	208	245
Current Liabilities and Provisions:		703,635	555,763
Short Term Credit Facility		-	-
Lease Finance (Current Portion)	8 (B)	518	596
Liabilities for Goods and Others		4,214	5,587
Liabilities for expenses	9	7,429	7,112
Liabilities for Other Finance	10	650,786	499,182
Provision for Income Tax	11	25,989	25,164
Workers Profit Participation Fund	12	14,232	13,121
Advance Received Against Export Sales		-	4,625
Unclaim Dividend		466	376
Total Equity And Liabilities		738,612	589,945
Net Asset Value per share (NAV)		12.58	12.26

Sd/-
(Kazi Tanzzina Ferdous)
Managing Director & CEO

Sd/-
(Sakina Miraly)
Director

Sd/-
(Nurjahan Hudda)
Director

Sd/-
(A.K.M Khairul Aziz)
Chief Financial Officer

Sd/-
(Mohammad Amir Hossain)
Company Secretary

Dhaka
January 22, 2025

Ambee Pharmaceuticals PLC
Statement of Comprehensive Income
For the 2nd Quarter ended 31st December 2024
(Unaudited)

Taka '000

<u>Particulars</u>	<u>Note</u>	<u>July-Dec 24</u>	<u>July-Dec 23</u>	<u>Oct-Dec 24</u>	<u>Oct-Dec 23</u>
Revenue (Turnover) from Net Sales		124,024	117,032	52,557	58,459
Cost of Goods Sold	13	(59,402)	(56,378)	(26,278)	(29,230)
Gross Profit		64,622	60,655	26,279	29,230
Operating Expenses :		(60,569)	(56,690)	(24,257)	(27,316)
Administrative Expenses	14	(10,506)	(10,270)	(6,191)	(6,886)
Marketing and Selling Expenses	15	(50,063)	(46,421)	(18,066)	(20,431)
Profit from Operation		4,053	3,964	2,021	1,913
Financial Expenses		(192)	(1,277)	(105)	(602)
Profit Before Contribution to WPPF		3,861	2,687	1,916	1,311
Contribution to WPPF		(193)	(135)	(96)	(66)
Net Profit before income-tax		3,668	2,553	1,820	1,246
Provision for income -tax		(502)	346	(343)	203
Current Tax		(825)	(574)	(410)	(280)
Deferred Tax Income/ (Expenses)	Annexure-A	323	920	66	483
Net Profit after income-tax		3,166	2,898	1,477	1,448
Number of Shares		2,400	2,400	2,400	2,400
Earnings Per Share (EPS)	16	1.32	1.20	0.62	0.60

Sd/-
(Kazi Tanzina Ferdous)
Managing Director & CEO

Sd/-
(Sakina Miraly)
Director

Sd/-
(Nurjahan Hudda)
Director

Sd/-
(A.K.M Khairul Aziz)
Chief Financial Officer

Sd/-
(Mohammad Amir Hossain)
Company Secretary

Dhaka
January 22, 2025

Ambee Pharmaceuticals PLC
Statement of Changes in Equity
For the 2nd quarter ended 31st December, 2024
(Unaudited)

As at 31st December, 2024

Taka '000

	Share Capital	Tax Holiday Reserve	Retained Earning	Total
At 1st July 2023	24,000	5,134	291	29,425
Dividend for the year 2023-2024			(2,400)	(2,400)
Net Profit after income-tax July to December 2024	-	-	3,166	3,166
At 31st December 2024	24,000	5,134	1,057	30,191
At 30th June 2024	24,000	5,134	291	29,425

As at 31st December , 2023

Taka '000

	Share Capital	Tax Holiday Reserve	Retained Earning	Total
At 1st July 2023	24,000	5,134	(5,793)	23,341
Dividend for the year 2022-2023			(3,600)	(3,600)
Net Profit after income-tax July to December 2023	-	-	2,898	2,898
At 31st December 2023	24,000	5,134	(6,495)	22,639
At 30th June 2023	24,000	5,134	(5,793)	23,341

Sd/-
(Kazi Tanzzina Ferdous)
Managing Director & CEO

Sd/-
(Sakina Miraly)
Director

Sd/-
(Nurjahan Hudda)
Director

Sd/-
(A.K.M Khairul Aziz)
Chief Financial Officer

Sd/-
(Mohammad Amir Hossain)
Company Secretary

Ambee Pharmaceuticals PLC
Statement of Cash Flows
For the period from 01 July 2024 to 31st December 2024
(Un-audited)

		<i>Taka '000</i>	
		<i>2nd Quarter 2024-25</i>	<i>2nd Quarter 2023-24</i>
		<i>July-Dec. 2024</i>	<i>July-Dec. 2023</i>
Cash Flows from Operating Activities :			
Collection from turnover		100,147	114,657
Payments for cost and expenses		(144,218)	(124,792)
Finance Expenses		(192)	(1,277)
Income-tax paid/deducted at source		(2,628)	(2,055)
Cash Generated from Operating Activities :		(46,891)	(13,467)
Cash Flows from Investing Activities :			
Acquisition of Fixed Assets		(8,800)	-
FDR Investment		(50,000)	-
Cash Generated From Investment Activities		(58,800)	-
Cash Flows from Financing Activities :			
Short Term Credit Facility		-	(1,992)
Other Finance		151,604	23,044
Lease Finance		(115)	(85)
Dividend paid		(2,386)	3,400
Cash Generated From Financial Activities		149,103	24,367
Increase/(Decrease) in cash and cash equivalents		43,412	10,900
Opening cash and cash equivalents		32,742	28,568
Closing Cash and Bank balances		76,154	39,468
Net Operating cash flow per share	16	(19.54)	(5.61)
Components of Cash and Cash Equivalents			
Cash and Cash Equivalents		76,154	39,468
Total Cash and Cash Equivalents		76,154	39,468

Sd/-
(Kazi Tanzzina Ferdous)
Managing Director & CEO

Sd/-
(Sakina Miraly)
Director

Sd/-
(Nurjahan Hudda)
Director

Sd/-
(A.K.M Khairul Aziz)
Chief Financial Officer

Sd/-
(Mohammad Amir Hossain)
Company Secretary

Ambee Pharmaceuticals PLC
Selected Notes to the Financial Statement (Un-audited)
For the 2nd Quarter ended December 31,2024

1.00 About the Company

The Ambee Pharmaceuticals PLC (the "Company") was incorporated in Bangladesh as a Public Company on 4th February, 1976. It commenced commercial operation in 1978 and went for public issue of shares in 1986. The shares of the Company are listed in the Dhaka and Chittagong Stock Exchanges of Bangladesh.

The registered office of the Company is located at 184/1, Tejgaon I/A, Dhaka – 1208 and the manufacturing plant is located at same place at 184/1, Tejgaon I/A, Dhaka – 1208.

The principal activities of the Company were manufacturing of pharmaceuticals drugs and medicines and sales thereof.

The Company has 08 Sales center in all over the Bangladesh in different districts to keep the Company's Sales, marketing, distribution and financial activities vibrant and dynamic.

2.00 Basis of preparation of Financial Statements

These Financial Statements should be read in conjunction with the Annual Financial Statements as on 30 June 2024, as they provide an update of previously reported information .

The accounting policies and presentation used are consistent with those used in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). Where necessary, the comparative figures have been reclassified or extended from the previously reported interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The presentation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgement at the date of Interim Financial statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

AMBEE PHARMACEUTICALS PLC.
Schedule of Property, Plant & Equipment
For the year ended December 31, 2024

Note-03.00

Schedule-A

Particulars	Cost			Balance as on 31.12.2024	Rate %	Depreciation			Written Down Value as on 31.12.2024	
	Balance as on 01.07.2024	Addition during the	Adjustment the during			Balance as on 01.07.2024	Adjustme	Charged during the Year		Balance as on 31.12.2024
Existing Units -1										
Land	49,033,738	-	-	49,033,738	-	-	-	-	-	49,033,738
Leasehold Land	1,215,803	-	-	1,215,803	-	-	-	-	-	1,215,803
Factory Building	26,326,964	-	-	26,326,964	10	16,992,797	-	466,708	17,459,505	8,867,459
Plant and Machinery	62,248,702	8,695,000	-	70,943,702	20	54,064,086	-	818,462	54,882,548	16,061,154
Deep Tube Well	1,368,000	-	-	1,368,000	10	1,235,714	-	6,614	1,242,328	125,672
Diesel Generating Set	446,500	-	-	446,500	15	402,979	-	3,264	406,243	40,256
Loose Tools	98,001	-	-	98,001	10	96,100	-	95	96,195	1,806
Laboratory Equipment	3,977,036	-	-	3,977,036	10	2,757,088	-	60,997	2,818,086	1,158,950
Electrical Installation	556,455	-	-	556,455	10	361,504	-	9,748	371,252	185,203
Laboratory Glassware	41,626	-	-	41,626	10	41,557	-	3	41,560	65
Production Equipment	1,220,541	-	-	1,220,541	10	974,911	-	12,281	987,193	233,348
Transport and Vehicles	12,530,135	-	-	12,530,135	20	11,428,517	-	110,162	11,538,678	991,457
Motor Cycle	38,662,774	-	-	38,662,774	20	32,827,561	-	583,521	33,411,083	5,251,692
Furniture and Fixtures	3,510,681	-	-	3,510,681	10	2,972,871	-	26,890	2,999,761	510,919
Office Equipment	14,723,986	105,500	-	14,829,486	10	11,166,133	-	177,893	11,344,025	3,485,461
Office By-cycles	15,962	-	-	15,962	20	15,867	-	10	15,876	86
Books	98,060	-	-	98,060	10	94,020	-	202	94,222	3,838
Sub Total	216,074,963	8,800,500	-	224,875,463		135,431,704	-	2,276,852	137,708,557	87,166,907
Injectable (Ampoule) Unit -2										
Factory Building	3,627,409	-	-	3,627,409	10	1,841,404	-	89,300	1,930,705	1,696,704
Plant and Machinery	9,221,953	-	-	9,221,953	20	7,934,609	-	128,734	8,063,343	1,158,609
Production Equipment	80,500	-	-	80,500	10	71,046	-	473	71,519	8,981
Transport and Vehicles	2,235,000	-	-	2,235,000	20	2,218,954	-	1,605	2,220,559	14,441
Furniture and Fixture	930,903	-	-	930,903	10	839,286	-	4,581	843,867	87,036
Sub Total	16,095,764	-	-	16,095,764		12,905,300	-	224,693	13,129,992	2,965,772
Balance on 31 December 2024	232,170,727	8,800,500	-	240,971,227		148,337,004	-	2,501,544	150,838,548	90,132,679
Balance on 30 June 2024	229,969,447	2,201,280	-	232,170,727		142,493,912	-	5,843,092	148,337,004	83,833,723

Note : Depreciation Charged to :

- (a) Cost of Goods Sold (Note-13.00)
(b) Administrative Expenses (Note-14.00)

31-12-2024
1,602,865
898,678
2,501,544

	As at Dec. 31,2024	As at June 30, 2024
4.00 Inventories		
Raw & Packing materials (including Work in Process, Promotional Materials & Materials in Transit)	93,691	65,312
Finished goods	156,247	156,602
	249,938	221,914
5.00 Advance Income Tax:		
Opening Balance	21,297	19,578
Add: Addition during the year	2,618	4,354
	23,915	23,932
Less: Adjustment during the year	-	2,636
	23,915	21,297
6.00 Advances, Deposits and Pre-payments		
a) Advances	43,178	45,950
b) Deposit and Prepayments	46	2,296
	43,224	48,245
a) Advances		
Advances to staff	4,087	3,659
Advance Rent	118	180
Against purchases and expenses	32,375	31,239
Advance Against Machinery Purchase	6,500	-
Bengal Steel Works Ltd.	-	10,774
Ambee Films Ltd.	98	98
Sub total	43,178	45,950
b) Deposit and Prepayments		
L/C Margin	-	2,250
Guarantee Margin	21	21
Pre-payments	25	25
Sub total	46	2,296
7.00 Cash & Cash Equivalents		
In hand	24,885	31,170
At banks:	51,269	1,572
In current account	51,212	1,515
In in-operative account	57	57
	76,154	32,742
8.00 Lease Finance		
A. Non-Current Portion	208	245
	208	245
B. Current Position	518	596
	518	596
08.01 Lease (Right of Use Asset (ROU), Net		
Balance as at 1st July, 2024	841	126
Add: Addition During the Year	-	1,155
Add: Interest Accrued	37	140
Less: Depreciation Charged During the Year	115	580
Written Down Value as at 31st December, 2024	726	841
Lease Liabilities Recognized in Statement of Financial Position		
Lease Liability - Net off Current Maturity	208	245
Lease Liability - Current Maturity	518	596
	726	841
09.00 Liabilities for Expenses		
Details of above balance are given below:		
Accrued Expenses	7,026	6,709
Audit Fees	403	403
	7,429	7,112
10.00 Liabilities for other Finance		
Details of above balance are given below:		
Employees Income Tax	701	701
Provident Fund Payable	1,916	1,916
Loan from Mr. Aziz Mohammad Bhai	193,095	193,095
Loan from Kazi Tanzzina Ferdous	-	1,000
Loan from Ambee Ltd.	312,507	282,469
Loan from Bengal Steel Workd Ltd	122,566	-
Interest Payable	20,001	20,001
	650,786	499,182
11.00 Provision for Income Tax		
Opening Balance	25,164	31,540
Provision for the Period	825	3,759
Adjustment for the year	-	10,135
	25,989	25,164
12.00 Workers Profit Participation Fund (WPPF)		
Opening Balance	13,121	11,713
Provision for the Period	193	623
Interest during the Period	918	1,347
Less: Adjustment/ payment during the Period	-	(562)
	14,232	13,121

	Tk' 000	
	2nd Quarter ended Dec. 30,2024	2nd Quarter ended Dec. 30,2023
13.00 Cost of Goods Sold		
Materials	48,347	46,508
Factory Overhead	9,452	8,874
Depreciation	1,603	996
	59,402	56,378
14.00 ADMINISTRATIVE EXPENSES		
Salary and allowances	6,645	5,647
Travelling & Conveyance	561	455
Electricity, Gas and Water	725	690
Repairs and maintenance	543	497
Legal and professional & AGM expenses	382	360
Depreciation	899	1,893
Other Expenses	851	728
	10,606	10,270
15.00 SELLING, DISTRIBUTION AND MARKETING EXPENSES		
Salary and allowances	38,607	36,059
Rent, rates and taxes	1,578	1,406
Conveyance	2,451	2,214
Repairs and maintenance	903	708
Electricity, Gas and Water	897	883
Delivery expenses	4,071	3,687
Free Sample	1,020	908
Other Expenses	638	556
	50,165	46,421
16.00 EARNING PER SHARE (EPS)		
This is made up as follows:		
Earning attributable to the Ordinary Shareholders (Net profit after tax)	3,166	2,898
Weighted average number of Ordinary shares outstanding during the period	2,400	2,400
	1.31	1.20
Earning Per Share (EPS) Increase due to sales increase by 5.97 % from previous sales.		
17.00 NET OPERATING CASH FLOW PER SHARE (NOCFPS).		
Cash flows from net operating activities as per Statement of Cash flows	(46,891)	-13,467
Weighted average number of Ordinary shares outstanding during the period	2,400	2,400
	(19.54)	(5.61)

Net Operating Cash Flow Per Share (NOCFPS) decrease due to increase of payments for cost and expenses for the 2nd quarter ended 31st December by 35.17 %.

18.00 Key Management Personnel Compensation.

During the Period, the amount of compensation paid to Key Management Personnel including Board of Directors is as under (As Para 17 of IAS 24 Related Party Disclosures):

Short Term Employee Benefits	-	96,616
Post- Employment Benefits	-	-
Other Long-Term Benefits	-	-
Termination Benefits	-	-
Bonus	-	2,914
	-	99,530

There is no other benefits provided by the company to it's employees other than a contributory Provident Fund Scheme.

19.00 Related Party Transactions - Disclosure under IAS 24 "Related Party Disclosure"

The Company has entered into transactions with other entities that fall within the definition of related party as contained in IAS-24 "Related Party Disclosures". The Company opines that terms of related party transactions do not significantly differ from those that could have been obtained from third parties. Total transactions of the significant related parties as at 31st December 2024 were as follows:

Name of the Party	Relationship	Nature of Transaction	Opening Balance	Addition during the Period	Adjustment during the Period	Closing Balance
Aziz Mohammad Bhai	Chairman	Inter company Loan/ Receivable	193,094	-	-	193,094
Kazi Tanzzina Ferdous	Managing Director	Inter company Loan/ Receivable	1,000	-	1,000	-
Ambee Limited	Group Concern	Inter company Loan/ Receivable	282,469	16,029	-	298,498
Bengal Steel Works Limited	Group Concern	Inter company Loan/ Receivable	10,774	122,566	10,774	122,566
Ambee Films Limited	Group Concern	Inter company Loan/ Receivable	98	-	-	98
Total			487,435	138,595	11,774	614,256

20.00 Computation of Deferred Tax

Particulars	As at Dec 31, 2024	As at June 30, 2024
Carrying value of depreciable fixed assets	39,883	33,584
Tax base Value	(19,566)	(13,954)
Net taxable temporary difference- Liabilities	20,317	19,630
Temporary difference for IFRS 16: Lease	35	427
	20,352	20,057
Tax Rate	22.5%	22.5%
Deferred Tax Liability - Closing	4,579	4,513
Deferred Tax Liability- Opening	4,513	6,123
Deferred Tax Assets for the Period	66	(1,610)

21.00 Reconciliation of Cash Flows from Operating Activities (Indirect Method):

PARTICULARS	AMOUNT(Tk.)
CASH FLOW FROM OPERATING ACTIVITIES:	
Net profit / (loss) before income tax during the period	3,668
Depreciation on Right of Use Asset	115
Depreciation on Property, Plant & Equipment	2,502
Deffered Tax	66
	6,351
CHANGE IN WORKING CAPITAL:	(53,242)
(Increase) / Decrease Advance, deosit & prepayments	5,021
(Increase) / Decrease Advance Income Tax	(2,618)
(Increase) / Decrease Trade Receivable	(23,877)
(Increase) / Decrease Inventories	(28,024)
(Increase)/ Decrease Creditors and other payables	(1,373)
(Increase) / Decrease in Accrued Expenses	317
(Increase) / Decrease in Advance Against Export Sales	(4,625)
(Increase) / Decrease in Provision for Income Tax	825
(Increase) / Decrease in Wrokers Profit Participation Fund	1,111
Net cash flows from operating activities	(46,891)
Net oerating cash flows per share	(19.54)

Sd/-
(Kazi Tanzzina Ferdous)
Managing Director & CEO

Sd/-
(Sakina Miraly)
Director

Sd/-
(Nurjahan Hudda)
Director

Sd/-
(A.K.M Khairul Aziz)
Chief Financial Officer

Sd/-
(Mohammad Amir Hossain)
Company Secretary

Dhaka
January 22, 2025